What is the best "sleeper" biotech pick currently with potential, but essentially forgotten? | Biotech Message Board Posts
  • Here We Go Again: Apparently, it's just one of those years. We here in the Greater New Orleans Area now find ourselves "in the cone" for the 7th time this year. And while we more or less dodged bullets the first 6 times, it looks like this time Zeta is going to hit close enough to do damage. We can only hope it stays a relatively minor Cat 1 & weakens upon approach. But preparations are once again in order for those of us living along the central Gulf Coast. Members with family or other interests in the affected area are welcome to post on the new Hurricane Zeta Self-Help board we just set up. Good luck & stay safe! 

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  33213 of 34920  at  7/3/2020 6:06:01 PM  by

good_investor93


 In response to msg 33159 by  Biotech_Jim
view thread

Re: What is the best "sleeper" biotech pick currently with potential, but essentially forgotten?

ACAD, by far and away. It hasn't been forgotten, but I'd say it's still flying under the radar of biotech investors and watchers.

Its lead drug Nuplazid will see net sales of close to $500 million this year for an indication (Parkinson's psychosis, or PDP) that is almost orphan size.

Nuplazid will be approved later this year for dementia-related psychosis, an indication 10 to 20 times the size of PDP. There is no FDA-approved drug for dementia-related psychosis; Nuplazid will be the first, just as it is the first and only drug approved for PDP.

Unlike ITCI, whose drug Caplyta competes in a very crowded field, ACAD will soon have 2 whole markets without branded competition. Nuplazid is the safest antipsychotic on the market and the first selective serotonin inverse agonist to receive FDA approval.

Any day now we'll learn the results of its phase 3 MDD trial. If the data are good, Nuplazid will be on the market later next year for 3 different indications. Jefferies sees $7 billion peak sales for Nuplazid across indications. I think sales could top $10 billion.

More about ACAD:
-- it has no debt
-- it has an orphan drug, trofinetide, in phase 3 testing for Rett
-- it has collaborations with both Neuren and Vanderbilt University
-- the Baker brothers own nearly 42 million shares, their 2nd largest holding by share count


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 14     Views: 334
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
33214 Re: What is the best "sleeper" biotech pick currently with potential, but essentially forgotten? Paul777333 6 7/4/2020 9:49:14 AM
33215 Re: What is the best "sleeper" biotech pick currently with potential, but essentially forgotten? JoeFlow 9 7/4/2020 10:43:11 AM






Financial Market Data provided by
.
Loading...